OncoMatch/Clinical Trials/NCT03721068
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
Is NCT03721068 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including iC9.GD2.CAR.IL-15 T-cells and Cyclophosphamide for neuroblastoma.
Treatment: iC9.GD2.CAR.IL-15 T-cells · Cyclophosphamide · Fludarabine — The body has different ways of fighting infections and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are molecules that fight infections and protect your body from diseases caused by bacteria and toxic substances. Antibodies work by sticking to those bacteria or substances, which stops them from growing and causing bad effects. T cells are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected. Both antibodies and T cells have been used to treat patients with cancers. They both have shown promise, but neither alone has been enough to cure most patients. This multicenter study is designed to combine both T cells and antibodies in order to create a more effective treatment. The treatment that is being researched is called autologous T lymphocyte chimeric antigen receptor cells (CAR) cells targeted against the disialoganglioside (GD2) antigen that express Interleukin (IL)-15, and the inducible caspase 9 safety switch (iC9), also known as iC9.GD2.CAR.IL-15 T cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroblastoma
Osteosarcoma
Prior therapy
Must have received: aggressive multi-drug frontline therapy — frontline
First or greater relapse of neuroblastoma following completion of aggressive multi-drug frontline therapy. First episode of progressive neuroblastoma during aggressive multi-drug frontline therapy. Persistent/refractory neuroblastoma as defined by less than a complete response by the revised International Neuroblastoma Response Criteria (INRC) at the conclusion of at least 4 cycles of aggressive multidrug induction chemotherapy on or according to a high-risk neuroblastoma protocol (such as A3973 or ANBL0532).
Must have received: standard treatment
relapsed or refractory osteosarcoma that is not responsive to standard treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Emory - Winship Cancer Institute · Atlanta, Georgia
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill · Chapel Hill, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify